Forefront Wealth Management Inc. Takes $2.21 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forefront Wealth Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,097 shares of the biopharmaceutical company's stock, valued at approximately $2,206,000. Regeneron Pharmaceuticals comprises approximately 2.0% of Forefront Wealth Management Inc.'s investment portfolio, making the stock its 21st largest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Intact Investment Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $356,000. Principal Financial Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock valued at $181,961,000 after purchasing an additional 2,828 shares during the last quarter. Golden State Equity Partners raised its position in Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 1,272 shares during the period. Fagan Associates Inc. lifted its stake in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after purchasing an additional 3,832 shares during the last quarter. Finally, ABC Arbitrage SA bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $1,510,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. TD Cowen dropped their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Bernstein Bank lowered their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Up 0.9 %

NASDAQ:REGN traded up $6.00 during trading hours on Wednesday, reaching $640.14. 1,251,813 shares of the company traded hands, compared to its average volume of 640,911. Regeneron Pharmaceuticals, Inc. has a 1 year low of $630.62 and a 1 year high of $1,211.20. The stock has a market capitalization of $69.98 billion, a P/E ratio of 16.72, a P/E/G ratio of 2.34 and a beta of 0.27. The business's 50-day moving average price is $687.18 and its two-hundred day moving average price is $806.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $11.86 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.